Vascular Therapies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2001-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.vasculartx.com
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
Phase 3
Active, not recruiting
- Conditions
- Complication of HemodialysisArteriovenous FistulaEnd Stage Kidney DiseaseESRDChronic Kidney FailureEnd Stage Renal DiseaseComplication of Renal DialysisVascular Access Complication
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Vascular Therapies, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT05425056
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸The Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Lundquist Institute for Biomedical Innovation, Torrance, California, United States
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
Phase 3
Completed
- Conditions
- End Stage Kidney DiseaseArteriovenous FistulaEnd Stage Renal DiseaseESRDChronic Kidney FailureVascular Access ComplicationComplication of Renal DialysisComplication of Hemodialysis
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Vascular Therapies, Inc.
- Target Recruit Count
- 269
- Registration Number
- NCT02513303
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸AKDHC Medical Research Service, Phoenix, Arizona, United States
🇺🇸San Diego Institute of Medical Research, Escondido, California, United States
© Copyright 2025. All Rights Reserved by MedPath